Literature DB >> 11591763

Rudimentary TCR signaling triggers default IL-10 secretion by human Th1 cells.

G G Burrows1, Y K Chou, C Wang, J W Chang, T P Finn, N E Culbertson, J Kim, D N Bourdette, D A Lewinsohn, D M Lewinsohn, M Ikeda, T Yoshioka, C N Allen, H Offner, A A Vandenbark.   

Abstract

Understanding the process of inducing T cell activation has been hampered by the complex interactions between APC and inflammatory Th1 cells. To dissociate Ag-specific signaling through the TCR from costimulatory signaling, rTCR ligands (RTL) containing the alpha1 and beta1 domains of HLA-DR2b (DRA*0101:DRB1*1501) covalently linked with either the myelin basic protein peptide 85-99 (RTL303) or CABL-b3a2 (RTL311) peptides were constructed to provide a minimal ligand for peptide-specific TCRs. When incubated with peptide-specific Th1 cell clones in the absence of APC or costimulatory molecules, only the cognate RTL induced partial activation through the TCR. This partial activation included rapid TCR zeta-chain phosphorylation, calcium mobilization, and reduced extracellular signal-related kinase activity, as well as IL-10 production, but not proliferation or other obvious phenotypic changes. On restimulation with APC/peptide, the RTL-pretreated Th1 clones had reduced proliferation and secreted less IFN-gamma; IL-10 production persisted. These findings reveal for the first time the rudimentary signaling pattern delivered by initial engagement of the external TCR interface, which is further supplemented by coactivation molecules. Activation with RTLs provides a novel strategy for generating autoantigen-specific bystander suppression useful for treatment of complex autoimmune diseases.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11591763     DOI: 10.4049/jimmunol.167.8.4386

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  32 in total

Review 1.  Systemic immunomodulation of autoimmune disease using MHC-derived recombinant TCR ligands.

Authors:  Gregory G Burrows
Journal:  Curr Drug Targets Inflamm Allergy       Date:  2005-04

Review 2.  Recombinant T cell receptor ligands: immunomodulatory, neuroprotective and neuroregenerative effects suggest application as therapy for multiple sclerosis.

Authors:  Halina Offner; Sushmita Sinha; Chunhe Wang; Gregory G Burrows; Arthur A Vandenbark
Journal:  Rev Neurosci       Date:  2008       Impact factor: 4.353

3.  Dissection of the human multipotent adult progenitor cell secretome by proteomic analysis.

Authors:  Gregory G Burrows; Wouter Van't Hof; Laura F Newell; Ashok Reddy; Phillip A Wilmarth; Larry L David; Amy Raber; Annelies Bogaerts; Jef Pinxteren; Robert J Deans; Richard T Maziarz
Journal:  Stem Cells Transl Med       Date:  2013-08-27       Impact factor: 6.940

4.  A novel HLA-DRα1-MOG-35-55 construct treats experimental stroke.

Authors:  Gil Benedek; Wenbin Zhu; Nicole Libal; Amanda Casper; Xiaolin Yu; Roberto Meza-Romero; Arthur A Vandenbark; Nabil J Alkayed; Halina Offner
Journal:  Metab Brain Dis       Date:  2014-03       Impact factor: 3.584

5.  Rationally designed mutations convert complexes of human recombinant T cell receptor ligands into monomers that retain biological activity.

Authors:  Jianya Y Huan; Roberto Meza-Romero; Jeffery L Mooney; Yuan K Chou; David M Edwards; Cathleen Rich; Jason M Link; Arthur A Vandenbark; Dennis N Bourdette; Hans-Peter Bächinger; Gregory G Burrows
Journal:  J Chem Technol Biotechnol       Date:  2004-10-12       Impact factor: 3.174

6.  Antigen-specific therapy promotes repair of myelin and axonal damage in established EAE.

Authors:  Chunhe Wang; Bruce G Gold; Laurie J Kaler; Xiaolin Yu; Michael E Afentoulis; Gregory G Burrows; Arthur A Vandenbark; Dennis N Bourdette; Halina Offner
Journal:  J Neurochem       Date:  2006-08-03       Impact factor: 5.372

7.  DRα1-MOG-35-55 Reduces Permanent Ischemic Brain Injury.

Authors:  Jianyi Wang; Qing Ye; Jing Xu; Gil Benedek; Haiyue Zhang; Yuanyuan Yang; Huan Liu; Roberto Meza-Romero; Arthur A Vandenbark; Halina Offner; Yanqin Gao
Journal:  Transl Stroke Res       Date:  2016-12-17       Impact factor: 6.829

8.  Recombinant T cell receptor ligand treats experimental stroke.

Authors:  Sandhya Subramanian; Bing Zhang; Yasuharu Kosaka; Gregory G Burrows; Marjorie R Grafe; Arthur A Vandenbark; Patricia D Hurn; Halina Offner
Journal:  Stroke       Date:  2009-05-14       Impact factor: 7.914

9.  Prevention and treatment of experimental autoimmune encephalomyelitis with clonotypic CDR3 peptides: CD4(+) Foxp3(+) T-regulatory cells suppress interleukin-2-dependent expansion of myelin basic protein-specific T cells.

Authors:  Abigail C Buenafe; Shayne Andrew; Michael Afentoulis; Halina Offner; Arthur A Vandenbark
Journal:  Immunology       Date:  2010-01-06       Impact factor: 7.397

10.  Recombinant TCR ligand reverses clinical signs and CNS damage of EAE induced by recombinant human MOG.

Authors:  Sushmita Sinha; Sandhya Subramanian; Ashley Emerson-Webber; Maren Lindner; Gregory G Burrows; Marjorie Grafe; Christopher Linington; Arthur A Vandenbark; Claude C A Bernard; Halina Offner
Journal:  J Neuroimmune Pharmacol       Date:  2009-09-30       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.